DiaMedica Therapeutics, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. The company is headquartered in Minneapolis, Minnesota and currently employs 16 full-time employees. The company went IPO on 2008-01-04. The firm is focused on developing treatments for kidney diseases, such as acute ischemic stroke (AIS) and chronic kidney disease (CKD). The firm's lead product, DM199, is an active recombinant (synthetic) form of the human tissue kallikrein-1 (KLK1) protein for the treatment of AIS and CKD, including hypertensive nephrosclerosis (hypertension). KLK1 is a serine protease (protein) that plays a role in the regulation of diverse physiological processes, including blood flow, inflammation, fibrosis, oxidative stress, and neurogenesis, via a molecular mechanism that increases the production of nitric oxide and prostaglandin. The company has also identified a potential treatment for inflammatory diseases, DM300, which is in the early preclinical stage of development.